Earnings Call Summary | Pulse Biosciences(PLSE.US) Q2 2024 Earnings Conference
Earnings Call Summary | Pulse Biosciences(PLSE.US) Q2 2024 Earnings Conference
The following is a summary of the Pulse Biosciences Inc. (PLSE) Q2 2024 Earnings Call Transcript:
以下是Pulse Biosciences Inc.（pulse biosciences）2024年第二季度業績會議電話簡報摘要：
Financial Performance:
金融業績：
Pulse Biosciences reported cash and cash equivalents totaling $26.2 million as of June 30, 2024, compared to $58.7 million the previous year.
The company noted a total GAAP cost increase of $1.5 million to $11.7 million for Q2 2024, primarily driven by non-cash stock-based compensation.
Received $60 million in gross proceeds from a rights offering which closed in July 2024, not included in the reported cash balance.
截至2024年6月30日，Pulse Biosciences報告現金及現金等價物總計2620萬美元，相比上年的5870萬美元有所減少。
該公司註明，由於非現金股票補償的主要推動，2024年Q2的總GAAP成本增加了150萬美元，達到了1170萬美元。
從在2024年7月結束的配股中獲得了6000萬美元的募集總收益，該金額未計入報告的現金餘額。
Business Progress:
業務進展：
Completed first US soft tissue ablation cases under FDA clearance and received breakthrough device designation for a cardiac surgical system.
Expanded leadership team and moved headquarters to Miami, Florida.
Plans to initiate pivotal clinical trials for soft tissue ablation and a surgical system for atrial fibrillation in early 2025.
通過FDA的審批，完成了美國首例軟組織消融手術，同時還獲得了一種用於心臟手術的突破性設備認定。
擴充領導團隊並將總部遷至佛羅里達州邁阿密市。
計劃在2025年初啓動軟組織消融和房顫手術系統的關鍵性臨床試驗。
More details: Pulse Biosciences IR
更多詳情請參見Pulse Biosciences IR。
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：本文由AI生成。文章內容的準確性無法完全保證。有關更全面的詳細信息，請參閱IR網站。本文只是爲投資者提供參考，沒有任何指導或推薦建議。